tickrz reports
tickrz rank
C
Allergan plc (AGN)
Healthcare | Drugs
218.21  -1.70%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankC / 234Warren Buffett RankA / 73
Pure Value RankB / 233Dividend RankN/A
Moat RankB / 147Financial Strength RankB / 162
Growth RankA / 2Momentum RankD / 392
AGN vs DRUGS SECTOR & S&P 500
VALUATION
AGNSECTORS&P 500
P/E RATIO6.3435.719.28
EV/EBITDA RATIO49.7125.111.77
P/S RATIO4.97.12.03
P/B RATIO1.058.73.09
QUALITY
RETURN ON EQUITY15.72%16.98%13.82%
RETURN ON CAPITAL-1.71%26.23%10.04%
NET MARGIN-6.46%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0.95%
PAYOUT RATIO6.29%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY40%
INTEREST COVERAGE-0.51x
CURRENT RATIO1.21
GROWTH
5 YR EPS GROWTH79.31%
5 YR SPS GROWTH26.02%
5 YR BPS GROWTH50.01%
About tickrz
Key Concepts
Great Investors
Allergan plc 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank C / 234
Allergan plc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking B / 233Warren Buffett ranking A / 73
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Allergan plc's valuation score is comprised of a P/E ratio of 6.3x, a P/B ratio of 1.1x, a P/S ratio of 4.9x, and an EV/EBITDA ratio of 49.7x. Allergan plc ranks 233 out of the S&P 500 constituents on valuation--a relatively average score.Allergan plc ranks 73 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Allergan plc warrants further investigation.

quality
moat B / 147financial strength B / 162
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.Allergan plc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -0.51x, a debt/equity ratio of 40% and a Moat Rank of 147 translate to an average Financial Strength score.


momentum D / 392
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -6.21% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 392. Based on its 12 month stock performance, Allergan plc will not appeal to momentum investors.

yield N/A
value + yield
Unfortunately we do not have enough data to provide a dividend ranking for Allergan plc.

growth A / 2
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 79.3% 5 year annualized EPS growth, 26% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 50% speak to its impressive growth ranking.

Allergan plc (AGN)
Healthcare | Drugs
218.21  -1.70%


tickrz rank
C
VALUATION RATIOS
P/E Ratio6.34x
P/B Ratio1.05x
P/S Ratio4.9x
EV/EBITDA Ratio49.71x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0.95%
PAYOUT RATIO6.29%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY40%
INTEREST COVERAGE-0.51x
CURRENT RATIO1.21
MOAT
ROE15.72%
ROIC-1.71%
Net Margin-6.46%
GROWTH
5 YR EPS GROWTH79.31%
5 YR SPS GROWTH26.02%
5 YR BPS GROWTH50.01%

TICKRZ RANK
Allergan plc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Allergan plc's valuation score is comprised of a P/E ratio of 6.3x, a P/B ratio of 1.1x, a P/S ratio of 4.9x, and an EV/EBITDA ratio of 49.7x. Allergan plc ranks 233 out of the S&P 500 constituents on valuation--a relatively average score.

WARREN BUFFETT RANKING
Allergan plc ranks 73 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Allergan plc warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.

FINANCIAL STRENGTH
Allergan plc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -0.51x, a debt/equity ratio of 40% and a Moat Rank of 147 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -6.21% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 392. Based on its 12 month stock performance, Allergan plc will not appeal to momentum investors.

VALUE + YIELD
Unfortunately we do not have enough data to provide a dividend ranking for Allergan plc.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 79.3% 5 year annualized EPS growth, 26% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 50% speak to its impressive growth ranking.